[{"data":1,"prerenderedAt":226},["ShallowReactive",2],{"story-164223-en":3},{"id":4,"slug":5,"slugs":5,"currentSlug":5,"title":6,"subtitle":7,"coverImagesSmall":8,"coverImages":9,"content":37,"questions":38,"relatedArticles":63,"body_color":224,"card_color":225},"164223",null,"Abbott's FreeStyle Libre Momentum Faces Headwinds | Healthcare Supply Chain Implications for Sellers","- Abbott reports 6% earnings growth but stock declines 6% on Libre underperformance and Exact Sciences dilution; signals shifting demand in diabetes management category",[],[10,11,12,13,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29,27,30,31,32,33,34,35,36],"https://images.wsj.net/im-34062673/social","https://s.yimg.com/ny/api/res/1.2/FohptQw5YfXUBb2C240fmQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD0xMzUw/https://media.zenfs.com/en/moby_896/c16151d72592b5b9938bfb652c9aaf06","https://cdn.benzinga.com/files/images/story/2026/04/16/Abbott-Laboratories.jpeg","https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1251892842/image_1251892842.jpg?io=getty-c-w630","https://www.quiverquant.com/images/abt_rect_new.png","https://images.barrons.com/im-20267075?width=700&height=466","https://s.yimg.com/os/en/zacks.com/294ac5400447acbf80c7325a61f41736","https://www.theglobeandmail.com/resizer/v2/BANNWCMHUFDLNJRSTU36Z4MQOY.jpg?auth=6020de84e9b4c1dbd9087277f4fe706b28b318b86fcd521c755ae601f3fff0d4&width=560&quality=80","https://mma.prnewswire.com/media/2761216/Abbott_New_Logo.jpg?w=10000","https://grafa.com/_next/image?url=https%3A%2F%2Fs3.ap-southeast-2.amazonaws.com%2Fassets.hq.grafa.com%2FAbbot-industries-earnings-640x357.webp&w=1200&q=75","https://www.reuters.com/resizer/v2/VHAINYFPYVKLVKKXKICAWJTCJ4.jpg?auth=0e1131d0e6f3257ef886e5e21468dc7d3ff5a1a4aa384600bcc203f54b47648a&width=1920&quality=80","https://www.abbott.com/content/dam/corp/abbottglobal/en-us/hub-new/r5a-0039-ret-960x430.jpg","https://s.yimg.com/ny/api/res/1.2/ixgh_iyHrXkdtf0..RaDcA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTEyMDA7aD02MDA-/https://media.zenfs.com/en/stockstory_922/50dacd45543fdfb173bee15ba0da4c95","https://www.investors.com/wp-content/uploads/2018/03/Stock-abbot-01-company.jpg","https://media.kare11.com/assets/AssociatedPress/images/d2bbc552-627c-4856-bad8-413d9164d386/20260416T120021/d2bbc552-627c-4856-bad8-413d9164d386_750x422.png","https://stockstory.org/stockstory/company-image/ABT?size=1000x500","https://media.tegna-media.com/assets/AssociatedPress/images/d2bbc552-627c-4856-bad8-413d9164d386/20260416T120021/d2bbc552-627c-4856-bad8-413d9164d386_750x422.png","https://static.gurufocus.com/logos/0C0000096K.png?20","https://imgproxy.divecdn.com/4B5kLKTjyQnc61-nj0BUNdDveNUuN2rH_gJjNtO2NTE/g:ce/rs:fill:1200:675:1/Z3M6Ly9kaXZlc2l0ZS1zdG9yYWdlL2RpdmVpbWFnZS9FeGFjdF9TY2llbmNlc19MYWIuanBlZw==.webp","https://blog-meyka-wordpress.s3.us-east-2.amazonaws.com/wp-content/uploads/2026/04/featured_image-4444.png","https://www.marketbeat.com/logos/abbott-laboratories-logo-1200x675.jpg","https://static.seekingalpha.com/cdn/s3/uploads/getty_images/532963888/image_532963888.jpg?io=getty-c-w1280","https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1325784605/image_1325784605.jpg?io=getty-c-w630","https://cdn.ttweb.net/News/images/386090.jpg?preset=w800_q70","https://cloudfront-us-east-1.images.arcpublishing.com/crain/CJIB7XNB7NEDLBHZV4KFABVWLE.jpg","https://img-s-msn-com.akamaized.net/tenant/amp/entityid/AA212oda.img?w=768&h=512&m=6","https://s.yimg.com/os/en/reuters.com/625c3124658fb6ae8f5b93d691860122","Abbott Laboratories' Q1 2026 results reveal a critical market divergence with direct implications for health and wellness e-commerce sellers. The company reported adjusted EPS of $1.15 (6% growth) and $11.164 billion in sales (7.8% reported growth), beating analyst expectations, yet the stock fell 6% on April 16, 2026, signaling investor concerns about operational execution and capital allocation strategy.\n\n**The core issue: FreeStyle Libre underperformance.** Abbott's flagship continuous glucose monitoring (CGM) system—positioned as a growth driver through dual-sensor variants (Libre 3 with 14-day wear for ages 4+, and Libre 3 Plus with 15-day wear and automated insulin dosing compatibility for ages 2+)—experienced \"lighter-than-expected sales\" in Q1 2026. This weakness in U.S. medical technology sales directly impacts the $2.1 billion diabetes management accessories market, where sellers source complementary products: sensor cases, adhesive patches, carrying pouches, smartphone stands, and vitamin C supplements (critical given Libre 3's \u003C500mg daily limit vs. Libre 3 Plus's 1000mg tolerance).\n\n**Acquisition-driven dilution compounds concerns.** Abbott's March 23, 2026 acquisition of Exact Sciences added $0.20 EPS dilution, reducing full-year 2026 guidance to $5.38-$5.58 from $5.55-$5.80. This 20-cent hit signals management prioritized strategic expansion into oncology diagnostics over near-term shareholder returns. The Nutrition segment declined 7.7% on comparable basis, reflecting \"lower sales volumes and strategic pricing actions\"—a pattern sellers should monitor for category-wide margin compression in health supplements and medical nutrition products.\n\n**Market segmentation opportunity emerges.** While Libre sales disappointed overall, the dual-sensor strategy reveals Abbott's confidence in tiered market penetration: standard Libre 3 for broad accessibility, Libre 3 Plus for insulin-dependent patients requiring closed-loop integration. This mirrors successful e-commerce segmentation strategies where sellers offer budget and premium variants. The FreeDM2 trial demonstrated 0.6 HbA1c reduction vs. fingerstick monitoring, validating clinical superiority but failing to translate to expected Q1 sales velocity—suggesting market adoption may be slower than projected or competitive pressure from Medtronic and Dexcom is intensifying.\n\n**Seller implications across three segments:** (1) **Diabetes accessories sellers** face uncertain demand trajectory; Libre's Q1 miss suggests inventory planning should be conservative through Q2 2026. (2) **Medical device resellers** should monitor Abbott's 8.5% medical devices growth ($5.54B sales) as a leading indicator—this segment's softness signals broader U.S. healthcare spending caution. (3) **Nutrition/supplement sellers** must prepare for potential margin pressure as Abbott implements \"strategic pricing actions\" that may cascade to retail channels, compressing wholesale margins 3-5% through 2026.",[39,42,45,48,51,54,57,60],{"title":40,"answer":41,"author":5,"avatar":5,"time":5},"How does vitamin C supplementation affect FreeStyle Libre sensor accuracy?","Abbott provides specific vitamin C guidance for each Libre variant: Libre 3 Sensor users should limit vitamin C to under 500 mg daily to avoid affecting sensor accuracy, while Libre 3 Plus Sensor users can safely consume up to 1000 mg daily without impacting readings. This technical consideration is critical for sellers offering diabetes management accessories and supplements, as it creates distinct product bundling opportunities for each sensor variant. Sellers should ensure product descriptions clearly specify which Libre version is compatible with higher-dose vitamin C supplements.",{"title":43,"answer":44,"author":5,"avatar":5,"time":5},"What does Abbott's nutrition segment decline signal for health supplement sellers?","Abbott's Nutrition segment declined 6.0% on a reported basis and 7.7% on a comparable basis in Q1 2026, reflecting 'lower sales volumes and strategic pricing actions implemented in Q4 2025.' This pattern suggests Abbott is implementing margin-compression strategies that may cascade to retail channels and third-party sellers. Health supplement and medical nutrition sellers should prepare for potential wholesale margin pressure of 3-5% through 2026 and monitor competitor pricing actions. Conservative inventory planning and diversified supplier strategies are recommended to mitigate exposure to Abbott's pricing adjustments.",{"title":46,"answer":47,"author":5,"avatar":5,"time":5},"How does the Exact Sciences acquisition impact Abbott's 2026 financial guidance?","Abbott completed the Exact Sciences acquisition on March 23, 2026, adding oncology diagnostics capabilities but creating $0.20 EPS dilution for full-year 2026. The company reduced full-year adjusted EPS guidance to $5.38-$5.58 from previous $5.55-$5.80 forecast. Second-quarter guidance proved particularly weak at $1.25-$1.31 EPS vs. analyst projections of $1.36. While the acquisition strengthens Abbott's position in high-growth cancer diagnostics, the immediate shareholder dilution and weak near-term guidance explain the market's negative reaction despite beating Q1 estimates.",{"title":49,"answer":50,"author":5,"avatar":5,"time":5},"What specific weakness emerged in Abbott's medical devices segment?","Abbott's medical devices segment generated $5.54 billion in Q1 2026 sales with 8.5% growth, slightly exceeding forecasts overall. However, specific weakness emerged in the FreeStyle Libre glucose monitoring system for diabetics, which experienced 'lighter-than-expected sales.' U.S. medical technology sales overall showed softness that concerned investors. This underperformance in a flagship product category signals potential demand challenges in the broader diabetes management market and suggests competitive pressure from Medtronic and Dexcom may be intensifying.",{"title":52,"answer":53,"author":5,"avatar":5,"time":5},"Why did Abbott's stock fall 6% despite beating Q1 earnings estimates?","Abbott exceeded earnings expectations ($1.15 adjusted EPS vs. $1.14 estimate) but disappointed on forward guidance and operational trends. The company reduced full-year 2026 EPS guidance to $5.38-$5.58 from $5.55-$5.80 (20-cent dilution from Exact Sciences acquisition) and reported weakness in FreeStyle Libre sales—its flagship diabetes device. Investors prioritize sustainable business segment performance over short-term beats; the Libre underperformance signals structural demand challenges that cannot be quickly resolved, raising concerns about Abbott's ability to maintain growth momentum across its portfolio through 2026.",{"title":55,"answer":56,"author":5,"avatar":5,"time":5},"What are the two FreeStyle Libre 3 sensor variants and their market segments?","Abbott offers Libre 3 (14-day wear, ages 4+, real-time CGM with alarms but no automated insulin dosing compatibility) and Libre 3 Plus (15-day wear, ages 2+, with automated insulin dosing system integration). The dual-sensor strategy targets different patient populations: Libre 3 serves broader accessibility needs for general diabetes management, while Libre 3 Plus addresses insulin-dependent patients requiring closed-loop delivery systems. This tiered approach enables Abbott to capture market share across multiple diabetes management segments, though Q1 2026 sales underperformance suggests adoption velocity may be slower than projected.",{"title":58,"answer":59,"author":5,"avatar":5,"time":5},"What does the FreeDM2 trial result mean for Libre market positioning?","The FreeDM2 trial demonstrated that FreeStyle Libre users achieved 0.6 HbA1c reduction compared to fingerstick monitoring, validating the clinical superiority of continuous glucose monitoring over traditional blood glucose testing. This clinical evidence supports Abbott's growth narrative and justifies premium pricing for Libre devices. However, the Q1 2026 sales miss suggests clinical validation alone is insufficient to drive expected adoption velocity—market adoption may be constrained by insurance coverage, patient awareness, or competitive offerings from Medtronic and Dexcom. Sellers should monitor insurance reimbursement trends and patient education initiatives as leading indicators of future demand.",{"title":61,"answer":62,"author":5,"avatar":5,"time":5},"How should diabetes accessories sellers adjust inventory strategy based on Q1 results?","Given FreeStyle Libre's Q1 underperformance and Abbott's reduced guidance, diabetes accessories sellers (sensor cases, adhesive patches, carrying pouches, smartphone stands) should adopt conservative inventory planning through Q2 2026. The slower-than-expected sales velocity suggests demand may not meet previous projections. Sellers should: (1) reduce forward inventory commitments by 15-20% until Q2 trends clarify, (2) diversify product offerings to support competing CGM systems (Medtronic Guardian, Dexcom G7), and (3) monitor Abbott's Q2 2026 earnings (expected July 2026) for demand trajectory confirmation before committing to H2 2026 inventory.",[64,69,73,77,81,86,90,94,98,101,104,109,113,117,121,125,129,133,137,141,146,150,153,157,161,166,170,175,178,182,186,191,195,200,204,208,212,216,220],{"id":65,"title":66,"source":67,"logo":5,"time":68},759180,"Abbott trims 2026 profit forecast on Exact deal hit, shares fall By Reuters","https://www.investing.com/news/stock-market-news/abbott-results-beat-on-medical-device-boost-exact-deal-hits-forecast-4617849","7H AGO",{"id":70,"title":71,"source":72,"logo":12,"time":68},759181,"Abbott Labs Annual Guidance Cut Overshadows Earnings Beat, Stock Cracks - Abbott Laboratories (NYSE:ABT)","https://www.benzinga.com/markets/earnings/26/04/51865238/abbott-guidance-cut-overshadows-earnings-beat",{"id":74,"title":75,"source":76,"logo":20,"time":68},759182,"Abbott trims 2026 profit forecast on Exact deal hit, shares fall","https://www.reuters.com/business/healthcare-pharmaceuticals/abbott-first-quarter-results-beat-cancer-diagnostics-medical-device-strength-2026-04-16/",{"id":78,"title":79,"source":80,"logo":28,"time":68},759183,"Abbott lowers earnings forecast after $21B Exact Sciences buy","https://www.medtechdive.com/news/abbott-lowers-earnings-forecast-after-21b-exact-sciences-buy/817708/",{"id":82,"title":83,"source":84,"logo":5,"time":85},759140,"Abbott cuts 2026 EPS guidance due to Exact Sciences dilution, posts Q1 sales beat","https://www.massdevice.com/abbott-cuts-eps-guidance-q1-2026/","10H AGO",{"id":87,"title":88,"source":89,"logo":31,"time":68},759184,"Health Care ETFs take notice as Abbott Laboratories slides on earnings","https://seekingalpha.com/news/4575824-health-care-etfs-take-notice-as-abbott-laboratories-slides-on-earnings",{"id":91,"title":92,"source":93,"logo":5,"time":85},759141,"Abbott shares dip on soft current-quarter guide; Q1 results in line","https://www.streetinsider.com/Earnings/Abbott+shares+dip+on+soft+current-quarter+guide%3B+Q1+results+in+line/26321653.html",{"id":95,"title":96,"source":97,"logo":5,"time":68},759185,"Abbott Laboratories (ABT) Lowers Earnings Outlook Despite Revenue Growth","https://www.gurufocus.com/news/8797796/abbott-laboratories-abt-lowers-earnings-outlook-despite-revenue-growth?mobile=true%3Fmobile%3Dtrue&mobile=true",{"id":99,"title":75,"source":100,"logo":17,"time":85},759142,"https://www.theglobeandmail.com/business/article-abbott-trims-2026-profit-forecast-on-exact-deal-hit-shares-fall/",{"id":102,"title":75,"source":103,"logo":35,"time":68},759186,"https://www.msn.com/en-ca/health/other/abbott-trims-2026-profit-forecast-on-exact-deal-hit-shares-fall/ar-AA212v5p?ocid=finance-verthp-feeds",{"id":105,"title":106,"source":107,"logo":25,"time":108},759143,"Abbott Laboratories’s (NYSE:ABT) Q1 CY2026 Sales Top Estimates","https://stockstory.org/us/stocks/nyse/abt/news/earnings/abbott-laboratoriess-nyseabt-q1-cy2026-sales-top-estimates","11H AGO",{"id":110,"title":111,"source":112,"logo":29,"time":68},759187,"Abbott Laboratories (ABL.DE) Drops 4.7% on XETRA After Earnings","https://meyka.com/blog/abbott-laboratories-ablde-drops-47-on-xetra-after-earnings-1604/",{"id":114,"title":115,"source":116,"logo":14,"time":108},759144,"ABBOTT LABORATORIES ($ABT) Releases Q1 2026 Earnings","https://www.quiverquant.com/news/ABBOTT+LABORATORIES+%28%24ABT%29+Releases+Q1+2026+Earnings",{"id":118,"title":119,"source":120,"logo":21,"time":108},759166,"Q1 progress positions Abbott for accelerating growth in 2026","https://www.abbott.com/en-us/corpnewsroom/strategy-and-strength/q1-progress-positions-Abbott-for-accelerating-growth-in-2026",{"id":122,"title":123,"source":124,"logo":5,"time":68},759188,"Abbott Laboratories (ABT) Reports Strong Q1 Revenue Growth, EPS In-Line","https://www.gurufocus.com/news/8797569/abbott-laboratories-abt-reports-strong-q1-revenue-growth-eps-inline?mobile=true%3Fmobile%3Dtrue&mobile=true%3Fmobile%3Dtrue%3Fmobile%3Dtrue&mobile=true&mobile=true",{"id":126,"title":127,"source":128,"logo":32,"time":108},759145,"Abbott dips as Exact Sciences buyout hurts outlook (ABT:NYSE)","https://seekingalpha.com/news/4575661-abbott-cuts-2026-outlook-reflect-exact-buyout",{"id":130,"title":131,"source":132,"logo":18,"time":108},759167,"Abbott Reports First-Quarter 2026 Results; Updates Guidance to Reflect Acquisition of Exact Sciences","https://abbott.mediaroom.com/2026-04-16-Abbott-Reports-First-Quarter-2026-Results-Updates-Guidance-to-Reflect-Acquisition-of-Exact-Sciences",{"id":134,"title":135,"source":136,"logo":30,"time":108},759146,"Abbott Laboratories (NYSE:ABT) Updates Q2 2026 Earnings Guidance","https://www.marketbeat.com/instant-alerts/abbott-laboratories-nyseabt-updates-q2-2026-earnings-guidance-2026-04-16/",{"id":138,"title":139,"source":140,"logo":33,"time":108},759168,"Abbott Labs' Q1 sales up 7.8% to $11.16B","https://breakingthenews.net/Article/Abbott-Labs'-Q1-sales-up-7.8-to-dollar11.16B/66084021",{"id":142,"title":143,"source":144,"logo":19,"time":145},759147,"Abbott (ABT) reports Q1 2026 earnings & Exact Sciences close","https://grafa.com/en/news/united-states/abbott-abt-q1-2026-earnings-exact-sciences-acquisition","23H AGO",{"id":147,"title":131,"source":148,"logo":5,"time":149},759169,"https://finance.yahoo.com/sectors/healthcare/articles/abbott-reports-first-quarter-2026-113000060.html","12H AGO",{"id":151,"title":106,"source":152,"logo":22,"time":108},759148,"https://finance.yahoo.com/sectors/healthcare/articles/abbott-laboratories-nyse-abt-q1-115900320.html",{"id":154,"title":155,"source":156,"logo":5,"time":108},759149,"Abbott Laboratories (ABT) Stock: Q1 2026 Revenue Surpasses Expectations on Cancer Diagnostics Growth","https://parameter.io/abbott-laboratories-abt-stock-q1-2026-revenue-surpasses-expectations-on-cancer-diagnostics-growth/",{"id":158,"title":159,"source":160,"logo":5,"time":149},759170,"Abbott Labs shares fall as earnings beat offset by Exact Sciences acquisition drag","https://www.proactiveinvestors.com/companies/news/1090692/abbott-labs-shares-fall-as-earnings-beat-offset-by-exact-sciences-acquisition-drag-1090692.html",{"id":162,"title":163,"source":164,"logo":27,"time":165},759171,"Abbott Laboratories (ABT) Reports Q1 2026 Earnings with Mixed Re","https://www.gurufocus.com/news/8799007/abbott-laboratories-abt-reports-q1-2026-earnings-with-mixed-results","3H AGO",{"id":167,"title":168,"source":169,"logo":24,"time":108},759150,"Abbott: Q1 Earnings Snapshot","https://www.kare11.com/article/syndication/associatedpress/abbott-q1-earnings-snapshot/616-5d591477-ce2d-4187-b1f0-5889b459b55d",{"id":171,"title":172,"source":173,"logo":10,"time":174},759172,"Abbott Stock Falls After Results Show Pressure in Several Businesses","https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-04-16-2026/card/abbott-stock-falls-after-results-show-pressure-in-several-businesses-qeYnvSTVBqwVTRdYcnG6","4H AGO",{"id":176,"title":168,"source":177,"logo":26,"time":108},759151,"https://www.10tv.com/article/syndication/associatedpress/abbott-q1-earnings-snapshot/616-5d591477-ce2d-4187-b1f0-5889b459b55d",{"id":179,"title":180,"source":181,"logo":27,"time":174},759173,"Abbott Laboratories (ABT) Faces Investor Concerns After Earnings Update","https://www.gurufocus.com/news/8798864/abbott-laboratories-abt-faces-investor-concerns-after-earnings-update",{"id":183,"title":184,"source":185,"logo":36,"time":108},759152,"Abbott results beat on medical device boost, Exact deal hits forecast","https://finance.yahoo.com/sectors/healthcare/articles/abbott-results-beat-medical-device-114012648.html",{"id":187,"title":188,"source":189,"logo":13,"time":190},759174,"Abbott stock slips on guidance cut, ranks 10th in healthcare equipment Quant ratings (ABT:NYSE)","https://seekingalpha.com/news/4575853-abbott-stock-slips-on-guidance-cut-ranks-10th-in-healthcare-equipment-quant-ratings","5H AGO",{"id":192,"title":193,"source":194,"logo":5,"time":108},759153,"Abbott (ABT) Q1 2026 earnings rise on adjusted basis after Exact Sciences acquisition","https://www.stocktitan.net/sec-filings/ABT/8-k-abbott-laboratories-reports-material-event-b7437723524d.html",{"id":196,"title":197,"source":198,"logo":34,"time":199},759175,"Abbott cuts profit forecast in wake of Exact Sciences deal","https://www.modernhealthcare.com/medical-devices/mh-abbott-laboratories-profit-forecast-exact-sciences/","6H AGO",{"id":201,"title":202,"source":203,"logo":16,"time":199},759176,"Abbott Stock Falls Despite Q1 Earnings & Revenue Beat","https://finance.yahoo.com/markets/stocks/articles/abbott-stock-falls-despite-q1-171200129.html",{"id":205,"title":206,"source":207,"logo":15,"time":174},759374,"Abbott Earnings Beat Estimates. Why the Stock Is Slumping.","https://www.barrons.com/articles/abbott-labs-earnings-stock-price-c7c75582",{"id":209,"title":210,"source":211,"logo":5,"time":199},759177,"Leerink reiterates Abbott Labs stock rating at Market Perform By Investing.com","https://in.investing.com/news/stock-market-news/leerink-reiterates-abbott-labs-stock-rating-at-market-perform-93CH-5342115",{"id":213,"title":214,"source":215,"logo":23,"time":68},759375,"Abbott Laboratories Slammed On Its Post-Exact Sciences Guidance","https://www.investors.com/news/technology/abbott-laboratories-stock-abbott-laboratories-earnings-q1-2026/",{"id":217,"title":218,"source":219,"logo":11,"time":199},759178,"Abbott Laboratories Q1 2026 Earnings Call Summary","https://finance.yahoo.com/sectors/healthcare/articles/abbott-laboratories-q1-2026-earnings-164631420.html",{"id":221,"title":222,"source":223,"logo":5,"time":68},759179,"Abbott Laboratories (ABT) Reports Q1 Earnings In-Line with Expec","https://www.gurufocus.com/news/8797982/abbott-laboratories-abt-reports-q1-earnings-inline-with-expectations?mobile=true%3Fmobile%3Dtrue&mobile=true%3Fmobile%3Dtrue%3Fmobile%3Dtrue&mobile=true&mobile=true","#ec2fbdff","#ec2fbd4d",1776396652577]